Rezafungin acetate - Cidara Therapeutics

Drug Profile

Rezafungin acetate - Cidara Therapeutics

Alternative Names: Biafungin™; CD 101; CD 101 IV; CD 101 Topical; SP 3025

Latest Information Update: 19 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Seachaid Pharmaceuticals
  • Developer Cidara Therapeutics
  • Class Antifungals; Echinocandins; Small molecules
  • Mechanism of Action Glucan synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Candidiasis; Candidaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Candidiasis
  • Preclinical Aspergillosis
  • Discontinued Vulvovaginal candidiasis

Most Recent Events

  • 07 Jun 2018 Adverse events data from a phase II STRIVE trial in Candidiasis presented at the ASM Microbe 2018 (ASMM-2018)
  • 19 Mar 2018 Cidara Therapeutics plans the phase III ReSPECT trial for Candidiasis (Prophylaxis) Worldwide in June 2018
  • 19 Mar 2018 Topline efficacy and adverse events data from the phase II STRIVE trial in Candidiasis released by Cidara Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top